



**Canadian
Blood
Services**

BLOOD
PLASMA
STEM CELLS
ORGANS
& TISSUES

1800 Alta Vista Drive
Ottawa ON
K1G 4J5
Canada

INFORMATION ONLY

Discontinuation of Cryosupernatant Plasma (CSP)

Customer Letter # 2025-02

2025-01-27

Dear Colleagues:

Effective March 31, 2025, Canadian Blood Services will discontinue the production of cryosupernatant plasma (CSP) (product code E6088V00). This decision follows review of the medical literature, collaboration with various stakeholders, as well as decreased CSP demand. Additionally, the National Advisory Committee for Blood and Blood Products (NAC) issued recommendations in 2023 that supports the efficacy and safety of solvent detergent (S/D) treated plasma when used as part of plasmapheresis treatments in patients with Thrombotic Thrombocytopenic Purpura (TTP).

The main changes will be:

- On March 31, 2025, production of CSP for transfusion will discontinue.
- CSP will be available until inventory is depleted, which is estimated to occur November 2025.
- Once inventory is depleted, a follow-up customer letter will be issued, and updates will be made to the Circular of Information Plasma Components.

Cryoprecipitate will continue to be produced by Canadian Blood Services.

Please share a copy of this customer letter with healthcare professionals at your hospital who might be interested in this information.

This customer letter can also be viewed at www.blood.ca in the "Hospital Services" section. If you have questions about this letter, or if you require it in an accessible format, please contact your local hospital liaison specialist.

Sincerely,

Tanya Petraszko
Senior Medical Director, Medical Laboratory and Stem Cell Services